Abstract:Background Antipsychotic drugs improve schizophrenia symptoms and reduce the frequency of relapse, but treatment response is highly variable. Little is known about the genetic factors associated with treatment response. We did a genome-wide association study of antipsychotic treatment response in patients with schizophrenia. Methods The discovery cohort comprised patients with schizophrenia from 32 psychiatric hospitals in China that are part of the Chinese Antipsychotics Pharmacogenomics Consortium. Patients who met inclusion criteria were randomly assigned (1:1:1:1:1:1) to six groups (olanzapine, risperidone, quetiapine, aripiprazole, ziprasidone, and haloperidol or perphenazine; those assigned to haloperidol or perphenazine were subsequently assigned [1:1] to one or the other) for 6 weeks. Antipsychotic response was quantified with percentage change on the Positive and Negative Syndrome Scale. Single-nucleotide polymorphisms (SNPs) were tested for their association with treatment response. Linkage-disequilibrium-independent SNPs that exhibited potential associations (ie, p < 1 x 10(-5)) were tested in a validation cohort comprising patients from the Chinese Antipsychotics Pharmacogenetics Consortium from five collaborative hospitals, who were treated with olanzapine, risperidone, or aripiprazole for 8 weeks. Findings The discovery cohort contained 2413 patients and the validation cohort 1379 patients. In the discovery cohort, we identified three novel SNPs (rs72790443 in MEGF10 [p=1.37 x 10(-8)], rs1471786 in SLC1A1 [p=1.77 x 10(-8)], and rs9291547 in PCDH7 [p=4.48x 10(-8)]) that were associated with antipsychotic treatment response at a genome-wide significance level. These associations were confirmed in the validation cohort (p < 0.05). In the combined sample of the discovery and validation cohorts, we identified five novel loci showing genome-wide significant associations with general antipsychotic treatment response (rs72790443 in MEGF10 [p=1.40 x 10(-9)], rs1471786 in SLC1A1 [p=2.33 x 10(-9)], rs9291547 in PCDH7 [p=3.24 x rs9291547 in PCDH7 [p=3.24 x 10(-9)], rs12711680 in CNTNAP5 [p=2.12 x 10(-9)], and rs6444970 in TNIK [p=4.85 x 10(-8)]).], rs12711680 in CNTNAP5 [p=2.12 x 10(-8)], and rs6444970 in TNIK [p=4.85 x 10(-8)]). In antipsychotic-specific groups, after the combination of results from both samples, the rs2239063 SNP in CACNA1C was associated with treatment response to olanzapine (p=1.10 x 10(-8)), rs16921385 in SLC1A1 was associated with treatment response to risperidone (p=4.40 x 10(-8)), and rs17022006 in CNTN4 was associated with treatment response to aripiprazole (p=2.58 x 10(-8)). Interpretation We have identified genes related to synaptic function, neurotransmitter receptors, and schizophrenia risk that are associated with response to antipsychotics. These findings improve understanding of the mechanisms underlying treatment responses, and the identified biomarkers could eventually guide choice of antipsychotic in patients with schizophrenia.

COMT, 5-HTR2A, and SLC6A4 Mrna Expressions in First-Episode Antipsychotic-Naïve Schizophrenia and Association with Treatment Outcomes

Association of Telomere Length and Mitochondrial DNA Copy Number with Risperidone Treatment Response in First-Episode Antipsychotic-Naïve Schizophrenia

Association between COMT gene polymorphisms, clinical symptoms, and cognitive functions in Han Chinese patients with schizophrenia.

Morphological Changes in Gray Matter Volume Correlate with Catechol-O-methyl Transferase Gene Val158Met Polymorphism in First-Episode Treatment-Naïve Patients with Schizophrenia

Genetic Polymorphism in Catechol‐o‐methyltransferase Associated with the Functional Connectivity of Frontostriatal Circuits in First Episode Schizophrenia Patients

The Association of Catechol-O-methyl Transferase Gene Polymorphism with the Clinical Efficacy of Risperidone in the Treatment and Cognitive Function in Patients with Schizophrenia

Genetic Contribution of Catechol-O-methyltransferase in Dorsolateral Prefrontal Cortex Functional Changes in the First Episode Schizophrenia

Association Studies of Genomic Variants with Treatment Response to Risperidone, Clozapine, Quetiapine and Chlorpromazine in the Chinese Han Population

Association between a COMT polymorphism and clinical response to risperidone treatment: a pharmacogenetic study.

Pharacogenetic Effects of Dopamine Transporter Gene Polymorphisms on Response to Chlorpromazine and Clozapine and on Extrapyramidal Syndrome in Schizophrenia

Predictive Biomarkers for Antipsychotic Treatment Response in Early Phase of Schizophrenia: Multi-Omic Measures Linking Subcortical Covariant Network, Transcriptomic Signatures, and Peripheral Epigenetics

Further evidence of transmission disequilibrium of the catechol-O-methyl transferase (COMT) gene in schizophrenia in a Chinese population

Genetic Study of Neurocognitive Function in First-Episode Schizophrenia

Pharmacogenetics of Treatment in First-Episode Schizophrenia: D3 and 5-HT2C Receptor Polymorphisms Separately Associate with Positive and Negative Symptom Response

Analysis of correlation between 3 single nucleotide polymorphisms of catechol-O-methyltransferase gene and therapeutic effect of risperidone in first-episode schizophrenics

[Molecular Pharmacogenetic Studies of Drug Responses to Obsessive-Compulsive Disorder and Six Functional Genes].

Association Between Catechol-O-methyltransferase Genetic Variation and Functional Connectivity in Patients with First-Episode Schizophrenia

Association Study of Clinical Presentation in First-Episode Schizophrenia and Possible Candidate Genes in Chromosome 22

Association of Catechol-O-Methyltransferase Gene Polymorphisms with Schizophrenia and Negative Symptoms in A Chinese Population

Depression, Cytokine, and Cytokine by Treatment Interactions Modulate Gene Expression in Antipsychotic Naïve First Episode Psychosis

Five Novel Loci Associated with Antipsychotic Treatment Response in Patients with Schizophrenia: a Genome-Wide Association Study